Literature DB >> 24418803

Evaluating progress on longstanding issues.

Lindsey Cox1, J Quentin Clemens1.   

Abstract

In 2013, data began to emerge that shed light on several longstanding issues in female urology, from the safety of adrenergic receptor agonists and onabotulinumtoxinA for overactive bladder to the use of physical therapy and mesh suburethral slings for stress urinary incontinence.

Entities:  

Mesh：

Year:  2014        PMID： 24418803     DOI： 10.1038/nrurol.2013.320

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  9 in total

1.  A randomized trial of urodynamic testing before stress-incontinence surgery.

Authors:  Charles W Nager; Linda Brubaker; Heather J Litman; Halina M Zyczynski; R Edward Varner; Cindy Amundsen; Larry T Sirls; Peggy A Norton; Amy M Arisco; Toby C Chai; Philippe Zimmern; Matthew D Barber; Kimberly J Dandreo; Shawn A Menefee; Kimberly Kenton; Jerry Lowder; Holly E Richter; Salil Khandwala; Ingrid Nygaard; Stephen R Kraus; Harry W Johnson; Gary E Lemack; Marina Mihova; Michael E Albo; Elizabeth Mueller; Gary Sutkin; Tracey S Wilson; Yvonne Hsu; Thomas A Rozanski; Leslie M Rickey; David Rahn; Sharon Tennstedt; John W Kusek; E Ann Gormley
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

Review 2.  Update of AUA guideline on the surgical management of female stress urinary incontinence.

Authors:  Roger R Dmochowski; Jerry M Blaivas; E Ann Gormley; Saad Juma; Mickey M Karram; Deborah J Lightner; Karl M Luber; Eric S Rovner; David R Staskin; J Christian Winters; Rodney A Appell; Linda E Whetter
Journal:  J Urol       Date:  2010-03-29       Impact factor: 7.450

3.  Surgery versus physiotherapy for stress urinary incontinence.

Authors:  Julien Labrie; Bary L C M Berghmans; Kathelijn Fischer; Alfredo L Milani; Ileana van der Wijk; Dina J C Smalbraak; Astrid Vollebregt; René P Schellart; Giuseppe C M Graziosi; J Marinus van der Ploeg; Joseph F G M Brouns; E Stella M Tiersma; Annette G Groenendijk; Piet Scholten; Ben Willem Mol; Elisabeth E Blokhuis; Albert H Adriaanse; Aaltje Schram; Jan-Paul W R Roovers; Antoine L M Lagro-Janssen; Carl H van der Vaart
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

4.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Authors:  Victor W Nitti; Roger Dmochowski; Sender Herschorn; Peter Sand; Catherine Thompson; Christopher Nardo; Xiaohong Yan; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2012-12-14       Impact factor: 7.450

5.  Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

Authors:  Victor W Nitti; Stephen Auerbach; Nancy Martin; Alaina Calhoun; Misun Lee; Sender Herschorn
Journal:  J Urol       Date:  2012-10-16       Impact factor: 7.450

6.  Long-term outcomes following abdominal sacrocolpopexy for pelvic organ prolapse.

Authors:  Ingrid Nygaard; Linda Brubaker; Halina M Zyczynski; Geoffrey Cundiff; Holly Richter; Marie Gantz; Paul Fine; Shawn Menefee; Beri Ridgeway; Anthony Visco; Lauren Klein Warren; Min Zhang; Susan Meikle
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

7.  The effect of urodynamic testing on clinical diagnosis, treatment plan and outcomes in women undergoing stress urinary incontinence surgery.

Authors:  Larry T Sirls; Holly E Richter; Heather J Litman; Kimberly Kenton; Gary E Lemack; Emily S Lukacz; Stephen R Kraus; Howard B Goldman; Alison Weidner; Leslie Rickey; Peggy Norton; Halina M Zyczynski; John W Kusek
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

8.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Authors:  Vik Khullar; Gerard Amarenco; Javier C Angulo; Javier Cambronero; Kjetil Høye; Ian Milsom; Piotr Radziszewski; Tomasz Rechberger; Peter Boerrigter; Ted Drogendijk; Marianne Wooning; Christopher Chapple
Journal:  Eur Urol       Date:  2012-11-06       Impact factor: 20.096

9.  Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Authors:  V W Nitti; V Khullar; P van Kerrebroeck; S Herschorn; J Cambronero; J C Angulo; M B Blauwet; C Dorrepaal; E Siddiqui; N E Martin
Journal:  Int J Clin Pract       Date:  2013-05-21       Impact factor: 2.503
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.